Bayer Schering Pharma Aktiengesellschaft (SHR) 6-K Press Release

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the Month of September 2006

Commission file number: 001-16143

SCHERING AKTIENGESELLSCHAFT

Muellerstrasse 178

13353 Berlin

Federal Republic of Germany

(Address of principal executive offices)

[Indicate by check mark whether the registrant files or will file annual

reports under cover Form 20-F or Form 40-F.]

Form 20-F __X__Form 40-F _____

[Indicate by check mark whether the registrant by furnishing the information

contained in this Form is also thereby furnishing the information to the

Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934]

Yes _____No __X__

                                            
60;               

News Release

Extraordinary Stockholders’ Meeting of Schering AG

Stockholders pave the way for Bayer Schering Pharma

· Schering Supervisory Board elects Werner Wenning as Chairman

· Arthur Higgins named Management Board Chairman of the future Bayer Schering Pharma AG

Berlin - The Bayer Group has taken a further important step toward the planned integration of Schering. On Wednesday the Schering stockholders consented to the domination and profit and loss transfer agreement with Bayer subsidiary Dritte BV GmbH at an Extraordinary Stockholders’ Meeting. Said Bayer Management Board Chairman Werner Wenning: “Now the condition has been fulfilled for integrating Schering as quickly as possible.” The stockholders also resolved on the name change from Schering AG to “Bayer Schering Pharma Aktiengesellschaft” and elected new stockholders’ representatives to the Supervisory Board. At its constituent meeting on Thursday, the Schering Supervisory Board appointed Wenning its Chairman. It then appointed the Board of Management of the future Bayer Schering Pharma AG and named Arthur Higgins Chairman of the Board of Management.

The domination and profit and loss transfer agreement approved by the Extraordinary Stockholders’ Meeting still needs to be entered in the commercial register. This will clear the way for the complete integration of Schering into the Bayer Group.

New Management Board Chairman Higgins, who is also Management Board Chairman of Bayer HealthCare AG, said he is confident about the prospects for the future Bayer Schering Pharma AG: “We are convinced that together, Bayer and Schering can be a leading player in the highly attractive specialty pharmaceutical market.” According to Higgins, the combined company will be the world’s seventh

- 2 -

leading supplier of specialty pharmaceuticals and the global number seven in the biotechnology industry.

Following the constituent meeting of the Supervisory Board, a symbolic baton handover took place in Berlin in the presence of Schering managers. The outgoing Schering Management Board Chairman Dr. Hubertus Erlen presented his successor Higgins with the historic title deed issued in 1864 for the first factory on the current Schering site in Berlin.

On Thursday Werner Baumann and Dr. Gunnar Riemann from Bayer HealthCare were also appointed new members of the Schering Board of Management, on which current members Dr. Ulrich Köstlin and Professor Marc Rubin, MD will continue to serve.

The Schering Supervisory Board also appointed Dr. Hubertus Erlen as one of its two vice chairmen. In addition, the Extraordinary Stockholders’ Meeting elected the following stockholders’ representatives to the Supervisory Board for the first time: Professor Dr. Friedrich Berschauer, Chairman of the Board of Management of Bayer CropScience AG; Dr. Roland Hartwig, General Counsel of Bayer AG; Klaus Kühn, Member of the Board of Management of Bayer AG; and Achim Noack, Managing Director of Bayer Technology Services GmbH. Existing Supervisory Board members Dr. Karl-Hermann Baumann and Dr. Reiner Hagemann will continue to serve, as will all the current employee representatives.

Berlin,	September 14, 2006
ha	(2006-0469-E)

Contact:

Bayer AG:

Günter Forneck, phone +49 214 30 50446

Email: guenter.forneck.gf@bayer-ag.de

Schering AG:

Oliver Renner, phone +49 30 468 12431

Email: oliver.renner@schering.de

Verena von Bassewitz, phone +49 30 468 192206

Email: verena.vonbassewitz@schering.de

- 3 -

Important information from Bayer AG:

This is neither an offer to purchase nor a solicitation of an offer to sell shares or American depositary shares of Schering AG. At the time of commencement of the mandatory compensation offer, Dritte BV GmbH will file a tender offer statement with the U.S. Securities and Exchange Commission (SEC) with respect to the mandatory compensation offer and Schering AG will file a solicitation/recommendation statement on Schedule 14D-9 with the SEC in respect of the mandatory compensation offer. Investors and holders of shares and American depositary shares of Schering AG are strongly advised to read the tender offer statement and other relevant documents regarding the mandatory compensation offer filed with the SEC when they become available because they will contain important information. Investors and holders of shares and American depositary shares of Schering AG will be able to receive these documents when they become available free of charge at the SEC’s website (http://www.sec.gov), or at the website http://www.bayer.de.

This news release contains certain forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our reports files with the Frankfurt Stock Exchange and our reports filed with the SEC (incl. on Form 20-F). Bayer AG and Dritte BV GmbH do not assume any liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Important information from Schering AG:

Legal Instruction

After the proposed offer of cash compensation by Dritte BV GmbH, a wholly owned subsidiary of Bayer Aktiengesellschaft, in connection with the planned domination and profit and loss transfer agreement between Dritte BV GmbH and Schering Aktiengesellschaft, is made available to Schering Aktiengesellschaft shareholders, Schering Aktiengesellschaft will file with the U.S. Securities and Exchange Commission a solicitation/recommendation statement on Schedule 14D-9 with respect to the offer of cash compensation. Holders of ordinary shares and American depositary shares of Schering Aktiengesellschaft are advised to read such solicitation/recommendation statement when it becomes available because it will contain important information. Holders of ordinary shares and American depositary shares of Schering Aktiengesellschaft will be able to obtain such solicitation/recommendation statement and other filed documents when they become available free of charge at the U.S. Securities and Exchange Commission’s website (http://www.sec.gov) and at Schering Aktiengesellschaft’s website (http://www.schering.de).

Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and Schering AG’s plans and objectives to differ materially from those expressed or implied in the forward-looking statements. Certain factors that may cause such differences are discussed in our Form 20-F and Form 6-K reports filed with the U.S. Securities and Exchange Commission. Schering AG undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

In order to utilize the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995, Schering Aktiengesellschaft (the "Company") is providing the following cautionary statement. Except for historical information, statements contained in this Current Report on Form 6-K may constitute forward-looking statements. The words "believe", "anticipate", "expect", "intend", "estimate", "plan", "assume", "will", "may", "should", "risk" and other similar expressions are predictions of or indicate future events and future trends which do not relate to historical matters but identify forward-looking statements. In addition, this annual report includes forward-looking statements relating to our potential exposure to various types of market risks, such as foreign exchange rate risk, interest rate and other risks related to financial assets and liabilities and equity price risk. You should not rely on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in many cases, beyond our control and may cause our actual results, performance or achievements to differ materially from anticipated future results, performance or achievements expressed or implied by the forward-looking statements and from past results, performance or achievements. Certain factors that may cause such differences include but are not limited to the following:

-   governmental factors, including legislative and regulatory changes;

-   difficulties and uncertainties related to new product development;

-   delays and uncertainties in the product approval process;

-   factors affecting our ability to obtain or maintain patent or trademark protection for our key products and processes;

-   factors adversely affecting the sale of our key products, including safety or efficacy concerns, increased competition from other products or manufacturing or supply disruptions;

-   competitive factors, including pricing and product initiatives of our competitors;

-   legal factors, including product liability or other liability claims;

-   factors relating to the implementation of strategic, operational and organizational initiatives;

-   human resources factors, including our ability to attract and retain qualified personnel;

-   economic factors over which we have no control, including changes in inflation, interest rates and foreign currency exchange rates, and overall economic conditions particularly in areas such as Asia, Eastern Europe and Latin America;

-   adverse developments in our relationships with our development, manufacturing and marketing partners;

-   the impact of future investments, acquisitions and dispositions, and any delays, unexpected costs or other problems experienced in connection with such transactions, including any liabilities associated with the sale of our minority interest in Aventis CropScience;

-   changes in environmental laws and regulations, which could cause us to incur significant costs in connection with ongoing compliance or liability for remediation; and

-   other risks, uncertainties and factors inherent in our business.

These and other risks, uncertainties and factors are discussed in the Company's Form 20-F Annual Report and other filings with the Securities and Exchange Commission, including this Form 6-K. Shareholders and prospective investors are cautioned not to place undue reliance on these forward-looking statements which speak only as to the Company's judgment as of the date hereof. Any such forward-looking statements are not intended to give any assurance as to future results. The Company undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SCHERING AKTIENGESELLSCHAFT
By:	/s/ Dr. Christof Ehrhart
	Name:  Dr. Christof Ehrhart
	Title:     Head Corporate Communication  Schering AG

By:	/s/ Oliver Renner
	Name:  Oliver Renner
	Title:     Head Corporate Business Communication  Schering AG

Date: September 14th, 2006